Business
Appointment of Broker
Appointment of Broker.
About this update from Gunsynd Plc
[{"type":"text","content":"\n RNS Number : 9354V Syntopix Group plc 11 November 2010 \n \n\n \n \n\n\n\n\nPress Release\n\n\n11 November 2010\n\n\n\n\n \nSyntopix Group plc\n(\"Syntopix\" or \"the Company\")\n \nAppointment of Broker\n \nSyntopix Group plc (AIM:SYN), the company focused on topical antimicrobial innovations for products in the medicinal and consumer healthcare markets, today announces that the Company has appointed XCAP Securities Plc as the Company's Broker with immediate effect.\n \nZeus Capital Limited remains the Company's Nominated Adviser. \n \n- Ends -\n \nFor further information, please contact:\n \n\n\n\n\nSyntopix Group plc\n\n\n\n\n\n\n\nDr Stephen Jones, Chief Executive Officer\n\n\n+44 (0)845 125 9204\n\n\n\n\nTom Bannatyne, Chairman\n\n\nwww.syntopix.com\n\n\n\n\n \n\n\n\n\nZeus Capital Ltd\n\n\n\n\n\n\n\nAlex Clarkson\n\n\nTel: +44(0)161 831 1512 \n\n\n\n\nTom Rowley\n\n\nwww.zeuscapital.co.uk\n\n\n\n\n \n\n\n\n\nXCAP Securities Plc\n\n\n\n\n\n\n\nJohn Grant\n\n\nTel: +44(0) 207 101 7070 \n\n\n\n\nDavid Newton\n\n\nwww.xcapgroup.co.uk\n\n\n\n\n \n\nMedia enquiries:\n\n\n\n\nAbchurch Communications\n\n\n\n\n\n\n\nSarah Hollins / Simone Elviss / Claire Dickinson\n\n\nTel: +44 (0) 20 7398 7728\n\n\n\n\[email protected] \n\n\nwww.abchurch-group.com\n\n\n\n\n\nNotes to editors\nSyntopix is a specialised research and development company, focusing on topical antimicrobial innovations for the cosmetic, consumer healthcare and pharmaceutical markets. The Group was founded in 2003 as a spin-out from the University of Leeds by Dr Jon Cove and Dr Anne Eady, two of the world's leading experts in skin microbiology.\n \nSyntopix combines scientific excellence with an understanding of consumer need to identify and develop innovative compounds which have clinical efficacy and proven benefits for the treatment of acne, gingivitis and body odour. \n \nThe Group has 12 granted UK patents, a robust research pipeline, and a growing library of over 2,700 compounds (with established safety profiles) profiled both individually and in combination for their antimicrobial activity. \n \nSyntopix' shareholders include IP Group plc, The Wellco...